Non surgical treatment of Budd-Chiari syndrome: A review;Traitement non chirurgical du syndrome de Budd-Chiari

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 1, 2004, Pages 40-49

  Barrault, Camille ^a   Plessier, Aurélie ^a   Valla, Dominique ^a   Condat, Bertrand ^a,b  

^a BEAUJON HOSPITAL   (France)

^b Hopital Saint Camille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALTEPLASE; AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; CYPROTERONE ACETATE; DANAPAROID; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; LEPIRUDIN; PHOSPHOLIPID ANTIBODY; PIPOBROMAN; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTAMINE SULFATE; PROTEIN C; PROTEIN S; PROTHROMBIN; STREPTOKINASE; UNINDEXED DRUG; UROKINASE; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL PROSTHESIS; BUDD CHIARI SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; ENDOVASCULAR SURGERY; FOLLOW UP; HEPATIC VEIN; HUMAN; INFERIOR CAVA VEIN; LIVER TOXICITY; MYELOPROLIFERATIVE DISORDER; OUTCOMES RESEARCH; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMAPHERESIS; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SHUNTING; STENT; SURVIVAL RATE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 1542284522     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(04)94839-7     Document Type: Short Survey

References (85)

1. Bismuth H, Sherlock DJ. Portosystemic shunting versus liver transplantation for the Budd-Chiari syndrome. Ann Surg 1991;214:581-89.
2. Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999;30:84-9.
3. Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 2003;39:496-501.
4. Tang TJ, Batts KP, de Groen PC, Van Hoek B, Haagsma EB, Hop WCJ, et al. The prognostic value of histology in the assesment of patient with Budd-Chiari syndrome. J Hepatol 2001;35:338-43.
5. Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998;28:1191-8.
6. Dayal S, Pati HP, Pande GK, Sharma MP, Saraya AK. Multilineage hematopoietic stem cell defects in Budd-Chiari syndrome. J Hepatol 1997;26:293-7.
7. Gupta S, Blumgart LH, Hodgson HJ. Budd-Chiari syndrome: long term survival and factors affecting mortality. Q J Med 1986;60:781-91.
8. Valla D. Obstruction of the hepatic veins. Dig Dis 1990;8:226-39.
9. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 2000;32:865-71.
10. Condat B, Chaït Y, Cazals-Hatem D, Valla D, Brière J. Caractéristiques des syndromes myéloprolifératifs en cas de syndrome de Budd-Chiari et de thrombose de la veine porte: étude chez 128 malades consécutifs (résumé). Gastroenterol Clin Biol 2003,27:A27.
11. Colombi M, Radaelli F, Zochi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. Cancer 1991;67:2926-30.
12. Socié G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal hemoglobinuria: long term follow-up and prognostic factors. Lancet 1996;348:573-7.
13. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie J. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.
14. Khuroo MS, Datta DV. Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. Am J Med 1980;68:113-21.
15. Vons C, Smadja C, Franco D, Valla D, Rueff B, Benhamou JP. Successful pregnancy after Budd-Chiari syndrome. Lancet 1984;27;2-975.
16. Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-7.
17. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000;32:466-70.
18. Campbell DA, Rolles K, Jamieson N, O'Grady J, Wight D, Williams R, et al. Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988;166:511-8.
19. Elalamy I, Page Y, Viallon A, Tardy B, Conard J, Helft G. Diagnostic et gestion des thrombopénies induites par l'héparine. Aspects biologiques et cliniques. Rev Mal Respir 1999;16:961-74.
20. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92.
21. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic a PTT range. Blood 2000;96:846-51.
22. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with hepain-induced thrombocytopenia. Circulation 2001;103:1838-43.
23. De Ledinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB, et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut 1999;4:270-3.
24. Planas R, Arroyo V, Rimola A, Perez Ayuso RM, Rodes J. Acetyl salicylic acid supresses the renal hemodynamic effest and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983;84:247-52.
25. Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogene activator (rt-PA). Bone Marrow Transplant 1990;5:439-41.
26. Bearman SI, Shuhart MC, Hinds MS, McDonald B. Recombinant human tissue plasminogene activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow tranplantation. Blood. 1992;10:2458-62.
27. Ludlam CA, Bennett B, Fox KA, Lowe GD, Reid AW. Guidelines for the use of thrombolytic therapy. Blood Coagul Fibrinolysis 1995;6:273-85.
28. Valla D, El Younsi M, Azar N, Hadengue A, Zeitoun G, Boudeet MJ, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology 1997;25:814-9.
29. Fischer NC, McCafferty IM, Dolapci M, Wali M, Buckels JAC, Oliff SP, et al. Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut 1999;44:568-74.
30. Rector WG, Redeker AG. Direct transhepatic assesment of hepatic vein pressure and direction of flow using a thin needle in patients with cirrhosis and Budd-Chiari syndrome. An effective alternative to hepatic vein catheterization. Gastroenterology 1984;86:1395-9.
31. Chunqing Z, Lina F, Guoquan Z, Lin X, Zhaohai W, Tao J, et al. Ultrasonically guided percutaneous transhepatic vein stent placement for Budd-Chiari syndrome. JVIR 1999;10:933-94.
32. Ryu RK, Durham JD, Krysl J, Shrestha R, Everson GT, Stephens J, et al. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. JVIR 1999;10:799-805.
33. Perello A, Garcia-Pagan JC, Gilabert R, Suarez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132-9.
34. Rössle M, Siegerstetter V, Ochs A, Buggisch P, Grandt D. Treatment of the Budd-Chiari syndrome (BCS) with the transjugular intrahepatic portosystemic shunt (TIPS). J Hepatol 2002;36:194.
35. Köstering H, Brunner G, Heimburg P, Creutzfeld W. Thrombolysis in the Budd-Chiari syndrome induced by partial thrombosis of inferior vena cava and the hepatic vein. Dtsch Med Wochenschr 1971;96:1532-4.
36. Warren RL, Schlant RC, Wenger NK, Galambos JT. Treatment of Budd-Chiari syndrome with streptokinase. Gastroenterology 1972;62:200.
37. Sholar PW, Bell WR. Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Ann Intern Med 1985;103:539-41.
38. McMullin MF, Hillmen P, Jackson J, Ganly P, Luzzatto L. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal haemoglobinuria. J Intern Med 1994;235:85-9.
39. McKee M, Mayne EE, Crothers G, Callender ME. Budd-Chiari syndrome treated with acytelated streptokinase-plasminogen complex. J R Soc Med 1985;78:768-9.
40. Kwan T, Hansarg P. Recombinant tissue-plasminogen activator for acute Budd-Chiari syndrome secondary to paroxysmal nocturnal hemoglobinuria. N Y State J Med 1992;92:109-10.
41. Assouline D, Negrier C, Coguard I, Archimbaud E, Fiere D, Bret M, et al. Successfull systemic thrombolysis of hepatic vein thrombosis in a patient with promyelocytic leukemia treated with all-trans retinoic acid. Am J Hematol 1995;48:291-2.
42. Watanabe H, Shinzawa H, Saito T, Ishibashi M, Shirata N, Miyano S, et al. Successful emergency treatment with a transjugular intrahepatic portosystemic shunt for life-threatening Budd-Chiari syndrome with portal thrombotic obstruction. Hepatogastroenterology 2000;47:839-41.
43. Guerin JM, Meyer P. Need for early thrombolysis in Budd-Chiari syndrome. Gastroenterology 1988;94:1109.
44. Cassel GA, Morley JE. Hepatic vein thrombosis treated with streptokinase. South Afr Med J 1974;4:2319-23.
45. Mahmoud AE, Mendoza A, Meshikhes AN, Olliff S, West R, Neuberger J, et al. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM 1996;89:37-43.
46. Mitchell MC, Boitnott JK, Kaufman S, Cameron JL, Maddrey WC. Budd Chiari syndrome: etiology, diagnosis and management. Medicine 1982;61:199-218.
47. Sawamura R, Fernandes MI, Galvao LC, Goldani HA. Report of two cases of children with Budd-Chiari syndrome successfully treated with streptokinase. Arq Gastroenterol 1996;33:179-81.
48. Asante-Korang A, Sreeram N, McKay R, Arnold R. Thrombolysis with tissue-type plasminogen activator following cardiac surgery in children. Int J Cardiol 1992;35:317-22.
49. Hemming AW, Langer B, Greig P, Taylor BR, Adams R, Heathcote EJ. Treatment of Budd Chiari syndrome with porto-systemic shunt or liver transplantation. Am J Surg 1996;171:176-81.
50. Mörl M. On the diagnosis of the Budd-Chiari syndrome and cardiac cirrhosis. Endoscopy 1981;13:169-72.
51. Pawlak J, Palester-Chlebowczyk M, Michalowicz B, Elwertowski M, Malkowski P. Thrombolytic treatment of Budd-Chiari syndrome with portal venous thrombosis. Pol Arch Med Wewn 1993;89:171-7.
52. Maillard JN, Berthelot P. Syndrome aigu de Budd-Chiari. Tentatives thérapeutiques (à propos de 3 cas). Revue Med Chir Mal Foie 1969;44:29-34.
53. Flörkemeier V, Bloos K, Fischer R. Leber Magen Darm 1971;1:163.
54. Ringe B, Lang H, Oldhafer KJ, Gebel M, Flemming P, Georgii A, et al. Which is the best surgery for Budd Chiari syndrome: venous decompression or liver transplantation? A single center experience with 50 patients. Hepatology 1995;21:337-44.
55. Bützow GH, Burkhardt A, Novak D, Becker K. Obliterierende Erkrankungen des Leberuenen. Kasuistischev Beitrag zur Klinik, Diagnostik, Therapie und Pathogenese des Budd-Chiari-Syndromo. Dtsch Med Wschr 1976;101:329-34.
56. Jester HG, Witztke G, Weyrauch D. Fibrinolytische Therapie beim Budd-Chiari-Syndrom. In: Trubestein G. Fibrinolytic therapy. Stuttgart, New York: 1983:265-72.
57. Nardini A, Falco E, Celoria G, Neviani AL, Stefani R, gadducci G, et al. Subacute Budd-Chiari syndrome treated with rTPA. Considerations on a case. Minerva Chir 1993;48:1129-33.
58. Casciaro S, Ghio R, Balleari E, Boccaccio G. Thrombolytic therapy using r-TPA in Budd-Chiari syndrome in the course of myeloproliferative diseases. Minerva Cardioangiol 1998;46:241-53.
59. Stiens R, Helpap B, Muller R. Zur morphologie und ätiologie des Budd-Chiari syndrome. Münch Med Wschr 1973;115:40.
60. Asbeck F, Joist H, Lohrs U. Lebowenten thrombose und Ovulation Shemmer. Ein weiterer Fall von Budd-Chiari-Syndrome nach Einnahme eines oralem Kontrazeptivums. Med Klin 1972;67:82-5.
61. Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE. Liver transplantation for the Budd-Chiari syndrome. Ann Surg 1990;211:43-9.
62. Albaret P, Cavellat JF, Billabert D, Toulemonde JL, Guntz M. Les formes évolutives du syndrome de Budd-Chiari (à propos de 3 observations). Revue du CHU 1972;26-27:9-12.
63. Greenwood HL, Yrizzari JM, Hallett JW, Scoville GS. Urokinase treatment of Budd-Chiari syndrome. AJR 1983;141:1057-59.
64. Ilan Y, Oren R, Shouval D. Postpartum Budd-Chiari syndrome with prolonged hypercoagulability state. Am J Obst Gynecol 1990;162:1164-65.
65. Raju GS, Felver M, Olin JW, Satti SD. Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Am J Gastroenterol 1996;91:1262-3.
66. Venbrux AC, Mitchell SE, Savander JS, Lund GB, Trerotola SO, Newman J, et al. Long term results with the use of metallic stents in the inferior vena cava for treatment of Budd Chiafi syndrome. JVIR 1994;5:411-6.
67. Savader SJ, Venbrux AC, Klein AS, Osterman FA. Russell H. Morgan. Percutaneous intervention in portosystemic shunt in Budd Chiari syndrome (abstract). JVIR 1991;2:437.
68. Thompson NP. Emergency rescue hepatic transplantation following shunt surgery for Budd Chiari syndrome. Eur J Gastroenterol Hepatol 1994;6:835-7.
69. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Kobayashi N. Segmental obstruction of the hepatic inferior vena cava treated by transluminal angioplasty. Radiology 1983;149:91-6.
70. Fujihara Y, Sawada S, Koyama T, Tanabe Y, Saitou S, Katsube Y, et al. Clinical experience of percutaneous transluminal angioplasty and expandable metallic stent placement for Budd-Chiari syndrome with massive thrombus in the inferior vena cava; report of a case. Rinsho Hoshasen 1990;35:1435-8.
71. Sharma S, Loya YS, Daxini BV. Percutaneous ballon membranotomy combined with prolonged streptokinase infusion for management of inferior vena cava obstruction. Am Heart J 1992;12:515-28.
72. Ishiguchi T, Fukatsu H, Itoh S, Shimamoto K, Sakuma S. Budd-chiari syndrome with long segmental inferior vena cava obstruction: treatment with thrombolysis, angioplasty and intravascular stent. J Vasc Interv Radiol 1992;3:421-5.
73. Kohli V, Pande GK, Dev V, Reddy KS, Kaul U, Nundy S. Management of hepatic venous outflow obstruction. Lancet 1993;42:718-22.
74. Frank JW, Kamath PS, Stanson AW. Budd-Chiari syndrome: early intervention with angioplasty and thrombolytic therapy. Mayo Clin Proc 1994;69:877-81.
75. Griffith JF, Mahmoud AE, Cooper S, Elias E, West RJ, Olliff SP. Radiological intervention in Budd-Chiari syndrome: techniques and outcome in 18 patients. Clin Radiol 1996;51:775-84.
76. Yamada K, Nakamura K, Ogawa K, Kuroki S, Yamashita A, Morimoto A, et al. A case of Budd-Chiari syndrome successfully treated by transcatheter recanalization of the right hepatic vein and transjugular intrahepatic porto-systemic shunt. Radiat Med 1999;17:85-9.
77. Patel NH, Bradshaw B, Meissner M, Townsend MF. Posttraumatic Budd-Chiari syndrome treated with thrombolytic therapy and angioplasty. J Trauma 1996;40:294-8.
78. Mahmoud AE, Helmy AS, Billingham L, Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997;9:485-9.
79. Leebeek FW, Lameris JS, van Buuren HR, Gomez E, Madretsma S, Sonneveld P. Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a factor V leiden mutation treated by TIPS and thrombolysis. Br J Haematol 1998;102:929-31.
80. Martin LG, Henderson JM, Millikan WJ, Casarella WJ, Kaufman SL. Angioplasty for long-term treatment patients with Budd-Chiari syndrome. AJR 1990;154:1007-10.
81. Griffith JF, Mahmoud AE, Cooper S, Elias E, West RJ, Olliff P. Radiological intervention in Budd-Chiari syndrome: techniques and outcome in 18 patients. Clin Radiol 1996;51:775-84.
82. Xu K, He FX, Zhang HG, Zhang XT, Han MJ, Wang CR, et al. Budd-Chiari syndrome caused by obstruction of the hepatic inferior vena cava: immediate and 2-year transluminal angioplasty and metallic stent placement. Cardiovasc Intervent Radiol 1996;19:32-6.
83. Yang XL, Cheng TO, Chen CR. Succesful treatment by percutaneous balloon angioplasty of Budd-Chiari syndrome caused by membranous obstruction of inferior vena cava: 8-year follow-up study. JACC 1996;28:1720-4.
84. Bilbao JI, Pueyo JC, Longo JM, Arias M, Herrero JI, Benito A. Interventional therapeutic techniques in Budd-Chiari syndrome. Cardiovasc Intervent Radiol 1997;20:112-9.
85. Ganger DR, Klapman JB, McDonald V, Matalon TA, Kaur S, Rosenblat H, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis. Am J Gastroenterol 1999;94:603-8.